Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Peter Lamb, insider at Exelixis
Peter Lamb Insider Alerts

Get notified the next time Peter Lamb buys or sells Exelixis stock. Enter your email address below to get our daily insider buying and selling report.

Peter Lamb Insider Information

EVP of Exelixis
Peter Lamb, Ph.D., has served as Executive Vice President, Scientific Strategy and Chief Scientific Officer since February 2016. Previously, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. He has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. He has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.

What is Peter Lamb's net worth?

The estimated net worth of Peter Lamb is at least $577,732.32 as of October 16th, 2015. Dr. Lamb owns 36,473 shares of Exelixis stock worth more than $577,732 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Lamb may own. Learn More.

How do I contact Peter Lamb?

The corporate mailing address for Dr. Lamb and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]

Has Peter Lamb been buying or selling shares of Exelixis?

In the last ninety days, Peter Lamb has sold $1,900,475.00 in Exelixis stock. Most recently, Peter Lamb sold 47,500 shares of the business's stock in a transaction on Monday, November 15th. The shares were sold at an average price of $18.09, for a transaction totalling $859,275.00.

Who are Exelixis' active insiders?

Exelixis' insider roster includes Patrick Haley (EVP), Jeffrey Hessekiel (EVP), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), Gisela Schwab (CMO), and Jack Wyszomierski (Director).

Are insiders buying or selling shares of Exelixis?

In the last year, insiders at the biotechnology company sold shares 29 times. They sold a total of 1,195,698 shares worth more than $26,262,090.88. The most recent insider tranaction occured on November, 24th when EVP Patrick J Haley sold 17,236 shares worth more than $297,321.00. Insiders at Exelixis own 3.3 % of the company.

Information on this page was last updated on 11/24/2021.

Peter Lamb Insider Trading History at Exelixis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2021Sell47,500$18.09$859,275.00View SEC Filing Icon  
10/15/2021Sell47,500$21.92$1,041,200.00View SEC Filing Icon  
8/16/2021Sell55,000$18.44$1,014,200.00View SEC Filing Icon  
7/15/2021Sell60,000$17.47$1,048,200.00View SEC Filing Icon  
6/17/2021Sell60,000$22.18$1,330,800.00View SEC Filing Icon  
4/1/2021Sell60,000$22.96$1,377,600.00View SEC Filing Icon  
3/1/2021Sell65,000$22.11$1,437,150.00View SEC Filing Icon  
2/1/2021Sell65,000$22.08$1,435,200.00View SEC Filing Icon  
1/4/2021Sell65,000$20.32$1,320,800.00View SEC Filing Icon  
12/18/2020Sell65,000$20.01$1,300,650.00View SEC Filing Icon  
6/8/2020Sell26,000$22.56$586,560.00View SEC Filing Icon  
4/6/2020Sell50,000$17.26$863,000.00View SEC Filing Icon  
6/17/2019Sell217,404$20.59$4,476,348.36View SEC Filing Icon  
6/13/2019Sell27,596$20.03$552,747.88View SEC Filing Icon  
1/3/2017Sell70,000$14.65$1,025,500.00View SEC Filing Icon  
12/1/2016Sell70,000$16.66$1,166,200.00View SEC Filing Icon  
10/16/2015Sell51,549$5.80$298,984.2036,473View SEC Filing Icon  
10/13/2015Sell600$5.80$3,480.0036,473View SEC Filing Icon  
10/12/2015Sell300,276$5.84$1,753,611.8436,473View SEC Filing Icon  
See Full Table

Peter Lamb Buying and Selling Activity at Exelixis

This chart shows Peter Lamb's buying and selling at Exelixis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exelixis Company Overview

Exelixis logo
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.
Read More

Today's Range

Now: $15.84
Low: $15.74
High: $16.67

50 Day Range

MA: $19.70
Low: $15.84
High: $21.88

2 Week Range

Now: $15.84
Low: $15.74
High: $25.77

Volume

2,503,907 shs

Average Volume

1,688,255 shs

Market Capitalization

$5.01 billion

P/E Ratio

31.06

Dividend Yield

N/A

Beta

0.87
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!